• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cost Effectiveness of Strategies to Manage Atrial Fibrillation in Middle- and High-Income Countries: A Systematic Review
ConclusionThis systematic review has shown that there are several cost-effective strategies to manage AF in different resource settings. However, the decision to use any strategy should be guided by objective clinical and economic evidence supported by sound clinical judgement.RegistrationCRD42022360590.
Source: PharmacoEconomics - May 19, 2023 Category: Health Management Source Type: research

Is Aberrant Reno-Renal Reflex Control of Blood Pressure a Contributor to Chronic Intermittent Hypoxia-Induced Hypertension?
This study demonstrated unaltered vascular conductance in response to lumbar sympathetic stimulation in CIH-exposed rats. Aortic compliance was increased and estimated blood volume was unchanged in CIH-exposed rats. Increased blood pressure was related to an increase in cardiac output, which was confirmed by echocardiography (Lucking et al., 2014). It is suggested therefore that hypertension in the CIH model can be evoked by over-excitation of the cardiac arm of sympathetic nervous system (SNS), even before mechanisms of enhanced peripheral vasoconstriction and endothelial dysfunction are initiated (Naghshin et al., 2009)....
Source: Frontiers in Physiology - April 23, 2019 Category: Physiology Source Type: research

Pharmacotherapy for hypertension in adults aged 18 to 59 years.
CONCLUSIONS: Antihypertensive drugs used to treat predominantly healthy adults aged 18 to 59 years with mild to moderate primary hypertension have a small absolute effect to reduce cardiovascular mortality and morbidity primarily due to reduction in cerebrovascular mortality and morbidity. All-cause mortality and coronary heart disease were not reduced. There is lack of good evidence on withdrawal due to adverse events. Future trials in this age group should be at least 10 years in duration and should compare different first-line drug classes and strategies. PMID: 28813123 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - August 16, 2017 Category: General Medicine Authors: Musini VM, Gueyffier F, Puil L, Salzwedel DM, Wright JM Tags: Cochrane Database Syst Rev Source Type: research

Beta-blockers in Pediatric Hypertrophic Cardiomyopathies.
Conclusions: Beta-blocker therapy is without doubt the treatment of choice for patients with heart failure caused by hypertrophic cardiomyopathy, but the dose needs to carefully titrated on an individual basis for maximum benefit, and the dose required is surprisingly large in infants with heart failure due to hypertrophic cardiomyopathy. PMID: 25198737 [PubMed - as supplied by publisher]
Source: Reviews on Recent Clinical Trials - September 8, 2014 Category: Cancer & Oncology Authors: Ostman-Smith I Tags: Rev Recent Clin Trials Source Type: research

Increase in parasympathetic tone by pyridostigmine prevents ventricular dysfunction during the onset of heart failure
Heart failure (HF) is characterized by elevated sympathetic activity and reduced parasympathetic control of the heart. Experimental evidence suggests that the increase in parasympathetic function can be a therapeutic alternative to slow HF evolution. The parasympathetic neurotransmission can be improved by acetylcholinesterase inhibition. We investigated the long-term (4 wk) effects of the acetylcholinesterase inhibitor pyridostigmine on sympathovagal balance, cardiac remodeling, and cardiac function in the onset of HF following myocardial infarction. Myocardial infarction was elicited in adult male Wistar rats. After 4 wk...
Source: AJP: Regulatory, Integrative and Comparative Physiology - October 15, 2013 Category: Physiology Authors: Lataro, R. M., Silva, C. A. A., Fazan, R., Rossi, M. A., Prado, C. M., Godinho, R. O., Salgado, H. C. Tags: Cardiovascular and Renal Integration Source Type: research

Increase in parasympathetic tone by pyridostigmine prevents ventricular dysfunction during the onset of heart failure.
Abstract Heart failure (HF) is characterized by elevated sympathetic activity and reduced parasympathetic control of the heart. Experimental evidence suggests that the increase in parasympathetic function can be a therapeutic alternative to slow HF evolution. The parasympathetic neurotransmission can be improved by acetylcholinesterase inhibition. We investigated the long term (four weeks) effects of the acetylcholinesterase inhibitor pyridostigmine on sympathovagal balance, cardiac remodeling and cardiac function in the onset of HF following myocardial infarction. Myocardial infarction was elicited in adult male ...
Source: American Journal of Physiology. Regulatory, Integrative and Comparative Physiology - August 15, 2013 Category: Physiology Authors: Lataro RM, Silva CA, Fazan R, Rossi MA, Prado CM, Godinho RO, Salgado HC Tags: Am J Physiol Regul Integr Comp Physiol Source Type: research